Community Guidelines

The @FightCancerNZ MSD New Zealand Twitter account is administered by MSD and a third-party service provider. Please note that we will respond to comments during business hours (9am-5pm, Monday to Friday). If you have an urgent enquiry regarding one of our medicines, please seek advice from a healthcare professional and follow the guidelines below.

We update and monitor this page keeping an eye out for anything that breaks the house rules or Twitter Terms of Service. The @FightCancerNZ MSD New Zealand Twitter account is not responsible for third party sites and makes no representation in relation to the accuracy, reliability, suitability, currency, completeness or lawful nature of such content.

We do not allow the use of the @FightCancerNZ MSD New Zealand Twitter account for any unauthorised third-party advertising or promotion, solicitation of donations or raising money, whether for a charity or otherwise.

 

House Rules

We welcome your contribution the @FightCancerNZ MSD New Zealand Twitter handle and we want to ensure that everyone understands the guidelines for participating. Your use is conditional upon you accepting and complying with these guidelines.

Some general considerations:

  • You need to be a registered member of Twitter and accept Twitter’s User Agreement to join the conversation
  • Please do not upload pictures of under 18s without consent or any other content that may be deemed irrelevant. Any content that MSD deems irrelevant (in its sole discretion) will be removed
  • Please don’t attempt to impersonate other people, well known or otherwise
  • Copyright, plagiarism and ownership – before you upload content please make sure you own the rights e.g. Images, video and music all need to be your own creation. If content is suspected not to be yours it will be removed.

MSD is part of a highly-regulated industry with unique legal considerations. We are governed by the Medicines New Zealand Code of Conduct and the Medicines Act, which means we cannot engage in conversations about our products, other companies’ products or treatment options in the public domain. If you would like to discuss one of our medicines with us; contact our medical information team: DPOC.Australia@merck.com

The information on the @FightCancerNZ MSD twitter handle is provided for your general information only and does not constitute medical advice and should not be interpreted as treatment recommendations. You should not use or act on this information without first seeking proper information and advice from your qualified health provider.

In our community, discussions need to be constructive and not breach local legislation. For this reason, comments may be deleted for:

  • Naming (including generic names) our products or other companies’ products
  • Offering health or medical advice
  • Profanity, defamatory, libelous, offensive, abusive, discriminatory or demeaning content, including images, videos or links
  • Threatening, condoning violence or illegal behavior
  • Publishing personal information e.g. names (note this does not include tagging of profiles) email addresses, phone numbers, personal photos or videos
  • Publishing propriety, confidential, sensitive or non-public information
  • Violating copyright or intellectual property laws
  • Publishing false, inaccurate or misleading information
  • Publishing information that is commercial in nature, with an intent to sell products or services or recruit followers to other social communities
  • Being excessively repetitive and/or disruptive
  • Violating Twitters Terms of Service
  • MSD may remove your comments or posts for legal, editorial or operational reasons. We reserve the right to delete any posts or comments at our sole discretion

Please be aware that those who violate the above rules may be blocked from the @FightCancerNZ MSD Twitter handle. In this case, the user would no longer be able to follow our news or comment on our posts.

Twitter accounts that MSD follows and content that MSD favorites or retweets is not an indication of MSD’s endorsement of these accounts or the content they produce. Nor is it an indication that we are engaged in a business relationship with the content authors.

 

Safety information (side effects and product complaints)

If you believe you have experienced a side effect or quality concern from an MSD product and need medical advice, please consult your doctor. Additionally, you can report this to the MSD Medical Department at DPOC.Australia@merck.com or call NZ 0800 500 673.

 

Using and storing personal identifying information

MSD will not collect, store, disclose or share personal identifying information (such as your Twitter profile, unique ID, email) on the @FightCancerNZ MSD Twitter handle; unless we have obtained proper consent.

However, in the case of reporting any safety information (e.g. a side effect or product issue) we will need to store and use personally identifying information, such as your initials, location, health-related information or similar; in accordance with local and international regulations and MSD procedures.

This information is required to be submitted to the MSD pharmacovigilance department and/or regulatory authorities. We are also required to store your personal identifying information for auditing purposes. Any personal information collected by MSD will be handled in accordance with MSD’s Privacy Policy.

Merck Sharp & Dohme (New Zealand) Limited (“MSD”) will collect, record and use your personal information for the purposes of adhering to local and international regulations and MSD procedures. If you choose not to provide us with your personal information, we may not be able to fulfill these purposes. We will keep your personal information for only as long as is necessary to carry out the purposes described above (unless we are required or permitted by law to hold the information for a longer period). We may disclose your personal information to organisations who assist us and our affiliated companies (which may be located in other countries including the United States, United Kingdom, Singapore, South America, Poland, China or India). If you would like to know more about our privacy policy, including how to access and seek correction of the personal information MSD holds about you, how to complain about a breach of the New Zealand Privacy Principles, and how MSD handles such complaints, please go to


https://www.msdprivacy.com/nz/en/index.html
or contact our Privacy Officer at:
C/O MSD, PO Box 99-851, Newmarket, Auckland 1149, T +64 9 523 6000,
E msd_privacy_office@msd.com.

Our third-party service provider helps us manage comments and messages received via the @FightCancerNZ MSD twitter handle; which means that they have access to any personal identifying information you share with us. Third-party service providers are contractually bound and trained to ensure they follow the process adopted for the protection and security of our personal identifying information.

Please note that Twitter also has access to information you share with us. For more details please refer to the Twitter Privacy Policy.

Thank you for reading and following @FightCancerNZ on Twitter.

NZ-KEY-00291 DA2039MW First issued February 2020.

NZ-KEY-00328

+

Important Safety Information About KEYTRUDA® (pembrolizumab)

KEYTRUDA contains the active substance called pembrolizumab and is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Before you receive KEYTRUDA, tell your doctor if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or plan to have or have had a bone marrow (stem cell) transplant that used donor stem cells (allogeneic); have lung or breathing problems; have liver problems; or have any other medical problems.

If you are pregnant or plan to become pregnant, tell your doctor. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, your doctor will give you a pregnancy test before you start treatment. Use effective birth control during treatment and for at least 4 months after the final dose of KEYTRUDA. Tell your doctor right away if you think you may be pregnant, or you become pregnant during treatment with KEYTRUDA.

If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Your doctor will give you KEYTRUDA through an IV for about 30 minutes. Most people get KEYTRUDA every 3 weeks or every 6 weeks, depending on the dose you are given. Your doctor will decide how many treatments you need.

What are the possible side effects of KEYTRUDA?

KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Side effects may occur with KEYTRUDA. Serious side effects include: lung problems (or pneumonitis); intestinal problems (or colitis) that can lead to tears or holes in your intestine; liver problems (or hepatitis); hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas); kidney problems (including nephritis and kidney failure); skin problems; problems in other organs; infusion (IV) reactions that can sometimes be severe and life-threatening; rejection of a transplanted organ; and complications in people with a bone marrow transplant that uses donor stem cells (allogeneic). Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines and delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Common side effects in people who received KEYTRUDA include feeling tired; pain, including pain in muscles, bones, or joints and stomach area (abdominal) pain; decreased appetite; itching; diarrhoea; nausea; rash; fever; cough; shortness of breath; and constipation.

Common side effects reported in more than 1 in 5 people when KEYTRUDA was given in combination with certain chemotherapy medicines: hair loss, feeling tired, diarrhoea, decreased white blood cell count, joint pain, rash. Less common side effects can happen.

Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:

Lung problems (pneumonitis). Symptoms of pneumonitis may include shortness of breath, chest pain, or new or worse cough.

Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include diarrhoea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems, including hepatitis. Signs and symptoms of liver problems may include yellowing of your skin or the whites of your eyes, nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, or bleeding or bruising more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include rapid heartbeat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include change in the amount or color of your urine.

Skin problems. Signs of skin problems may include rash, itching, blisters, peeling or skin sores, or painful sores or ulcers in your mouth or in your nose, throat, or genital area.

Problems in other organs. Signs and symptoms of these problems may include changes in eyesight; severe or persistent muscle or joint pains; severe muscle weakness; low red blood cells (anemia); swollen lymph nodes, rash or tender lumps on skin, cough, shortness of breath, vision changes, or eye pain (sarcoidosis); confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures (encephalitis); and shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis).

Infusion (IV) reactions that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, shortness of breath or wheezing, itching or rash, flushing, dizziness, fever, or feeling like passing out.

Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection if they are treated with KEYTRUDA.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain, and diarrhoea.

Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Based on US Consumer SSI & NZ CMI and Data sheet prepared 29 July 2019.


KEYTRUDA (pembrolizumab) 50mg powder for infusion

KEYTRUDA (pembrolizumab) 100 mg/4 mL (25 mg/mL) concentrate for solution for infusion

KEYTRUDA is a Prescription Only Medicine

Use: KEYTRUDA is used
  • in the treatment of melanoma which cannot be removed by surgery alone or when it has spread to multiple sites in the body
  • in treatment of melanoma after surgery to help prevent the cancer from coming back
  • in the treatment of a kind of lung cancer called non-small cell lung cancer (NSCLC)
  • in the treatment of classical Hodgkin Lymphoma (cHL)
  • in the treatment of urothelial carcinoma, including bladder cancer
  • in the treatment of a kind of head and neck cancer called head and neck squamous cell carcinoma (HNSCC)
  • in the treatment of a kind of cancer in adults and children that can occur in any part of the body and is shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Side effects: Immune-mediated side effects including inflammation of the lungs, colon, liver, kidneys, pituitary gland, brain, eye, muscles, nervous system, pancreas, and heart, thyroid disorders, type 1 diabetes mellitus, adrenal insufficiency. Severe skin reactions including Steven-Johnson syndrome and toxic epidermal necrolysis. Severe infusion reactions including hypersensitivity and anaphylaxis. Transplant recipients: rejection of a transplanted organ, graft-versus-host-disease (in people with a bone marrow transplant using donor cells). Very common side effects include diarrhea, nausea, itching, rash, joint pain, back pain, feeling tired, cough, patches of discoloured skin, stomach pain, decreased levels of sodium in blood. Hair loss, tiredness, diarrhoea, a decrease in white-blood cell count, joint pain, and rash, were reported when given in combination with chemotherapy. Common side effects in children include fever, vomiting, fatigue, constipation stomach pain and nausea. It is not known if KEYTRUDA is safe and effective in children with MSI-H or dMMR cancer of the brain or spinal cord (central nervous system cancers). You may experience more than one side effect at the same time.

All medicines have risks and benefits. Talk to your doctor to see if KEYTRUDA is right for you. KEYTRUDA is a funded medicine for melanoma patients – restrictions apply. KEYTRUDA is an unfunded medicine for treatment of melanoma after surgery, NSCLC, HNSCC, cHL, urothelial carcinoma and MSI-H/dMMR cancer patients. Ask your health professional the cost of the medicine and any other medical fees that may apply. Use only as directed and if symptoms continue or you have side effects, see your doctor, pharmacist, or health professional.

Based on data sheet prepared 28 November 2019. Marketed by: Merck Sharp & Dohme (New Zealand) Limited, Newmarket, Auckland. For additional product information, consult the Consumer Medicine Information (CMI), available on request, phone 0800 500 673 or refer to the Medsafe website medsafe.govt.nz.

See full indications

KEYTRUDA (pembrolizumab) 50mg powder for infusion

KEYTRUDA (pembrolizumab) 100 mg/4 mL (25 mg/mL) concentrate for solution for infusion

KEYTRUDA is a Prescription Only Medicine and is used:

  • in the treatment of melanoma which cannot be removed by surgery alone or when it has spread to multiple sites in the body
  • in treatment of melanoma after surgery to help prevent the cancer from coming back.
  • in the treatment of a kind of lung cancer called non-small cell lung cancer (NSCLC)
  • in the treatment of classical Hodgkin Lymphoma (cHL)
  • in the treatment of urothelial carcinoma, including bladder cancer
  • in the treatment of a kind of head and neck cancer called head and neck squamous cell carcinoma (HNSCC)
  • in the treatment of a kind of cancer in adults and children that can occur in any part of the body and is shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
  • It is not known if KEYTRUDA is safe and effective in children with MSI-H or dMMR cancer of the brain or spinal cord (central nervous system cancers).

KEYTRUDA contains the active substance called pembrolizumab and is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Before you receive KEYTRUDA, tell your doctor if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or plan to have or have had a bone marrow (stem cell) transplant that used donor stem cells (allogeneic); have lung or breathing problems; have liver problems; or have any other medical problems. If you are pregnant or plan to become pregnant, tell your doctor. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, your doctor will give you a pregnancy test before you start treatment. Use effective birth control during treatment and for at least 4 months after the final dose of KEYTRUDA. Tell your doctor right away if you think you may be pregnant, or you become pregnant during treatment with KEYTRUDA. If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your doctor will give you KEYTRUDA through an IV for about 30 minutes. Most people get KEYTRUDA every 3 weeks or every 6 weeks, depending on the dose you are given. Your doctor will decide how many treatments you need.

What are the possible side effects of KEYTRUDA?

KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Side effects may occur with KEYTRUDA. Serious side effects include: lung problems (or pneumonitis); intestinal problems (or colitis) that can lead to tears or holes in your intestine; liver problems (or hepatitis); hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas); kidney problems (including nephritis and kidney failure); skin problems; problems in other organs; infusion (IV) reactions that can sometimes be severe and life-threatening; rejection of a transplanted organ; and complications in people with a bone marrow transplant that uses donor stem cells (allogeneic). Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines and delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Common side effects in people who received KEYTRUDA include feeling tired; pain, including pain in muscles, bones, or joints and stomach area (abdominal) pain; decreased appetite; itching; diarrhea; nausea; rash; fever; cough; shortness of breath; and constipation.

Common side effects reported in more than 1 in 5 people when KEYTRUDA was given in combination with certain chemotherapy medicines: hair loss, feeling tired, diarrhea, decreased white blood cell count, joint pain, Rash. Less common side effects can happen.

Call or see your doctor right away if you develop any symptoms of the following problems or these symptoms get worse:

Lung problems (pneumonitis). Symptoms of pneumonitis may include shortness of breath, chest pain, or new or worse cough.

Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include diarrhea or more bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems, including hepatitis. Signs and symptoms of liver problems may include yellowing of your skin or the whites of your eyes, nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine, or bleeding or bruising more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include rapid heartbeat, weight loss or weight gain, increased sweating, feeling more hungry or thirsty, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include change in the amount or color of your urine.

Skin problems. Signs of skin problems may include rash, itching, blisters, peeling or skin sores, or painful sores or ulcers in your mouth or in your nose, throat, or genital area.

Problems in other organs. Signs and symptoms of these problems may include changes in eyesight; severe or persistent muscle or joint pains; severe muscle weakness; low red blood cells (anemia); swollen lymph nodes, rash or tender lumps on skin, cough, shortness of breath, vision changes, or eye pain (sarcoidosis); confusion, fever, muscle weakness, balance problems, nausea, vomiting, stiff neck, memory problems, or seizures (encephalitis); and shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis).

Infusion (IV) reactions that can sometimes be severe and life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, shortness of breath or wheezing, itching or rash, flushing, dizziness, fever, or feeling like passing out.

Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection if they are treated with KEYTRUDA.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain, and diarrhea.

Getting medical treatment right away may help keep these problems from becoming more serious. Your doctor will check you for these problems during treatment with KEYTRUDA. Your doctor may treat you with corticosteroid or hormone replacement medicines. Your doctor may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

KEYTRUDA is an unfunded medicine for treatment of melanoma after surgery, NSCLC, HNSCC, cHL, urothelial carcinoma and MSI-H/dMMR cancer patients

Based on US Consumer SSI & NZ CMI and Data sheet prepared 28th November 2019

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. NZ-KEY-00266 TAPS NA 11575 First issued November 2017 essence MSD9432 Updated: January 2020.